338 related articles for article (PubMed ID: 16363238)
41. How should we determine length of anticoagulation after proximal deep vein thrombosis of the lower limbs?
Siragusa S; Caramazza D; Malato A
Br J Haematol; 2009 Mar; 144(6):832-7. PubMed ID: 19183183
[TBL] [Abstract][Full Text] [Related]
42. Kinetics of D-dimer after general surgery.
Dindo D; Breitenstein S; Hahnloser D; Seifert B; Yakarisik S; Asmis LM; Muller MK; Clavien PA
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):347-52. PubMed ID: 19474701
[TBL] [Abstract][Full Text] [Related]
43. Deep vein thrombosis after total hip arthroplasty in Korean patients and D-dimer as a screening tool.
Yoo MC; Cho YJ; Ghanem E; Ramteke A; Kim KI
Arch Orthop Trauma Surg; 2009 Jul; 129(7):887-94. PubMed ID: 18825397
[TBL] [Abstract][Full Text] [Related]
44. The use of D-dimer in specific clinical conditions: a narrative review.
Bruinstroop E; van de Ree MA; Huisman MV
Eur J Intern Med; 2009 Sep; 20(5):441-6. PubMed ID: 19712840
[TBL] [Abstract][Full Text] [Related]
45. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
[TBL] [Abstract][Full Text] [Related]
46. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy.
Sallah S; Husain A; Sigounas V; Wan J; Turturro F; Sigounas G; Nguyen NP
Clin Cancer Res; 2004 Nov; 10(21):7238-43. PubMed ID: 15534097
[TBL] [Abstract][Full Text] [Related]
47. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia.
Vossen CY; Walker ID; Svensson P; Souto JC; Scharrer I; Preston FE; Palareti G; Pabinger I; van der Meer FJ; Makris M; Fontcuberta J; Conard J; Rosendaal FR
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1992-7. PubMed ID: 15976329
[TBL] [Abstract][Full Text] [Related]
48. Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis.
Elf JL; Strandberg K; Svensson PJ
Thromb Res; 2009 Dec; 124(6):701-5. PubMed ID: 19682729
[TBL] [Abstract][Full Text] [Related]
49. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E
Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311
[TBL] [Abstract][Full Text] [Related]
50. High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes.
Paneesha S; Cheyne E; French K; Bacchu S; Borg A; Rose P
Br J Haematol; 2006 Oct; 135(1):85-90. PubMed ID: 16925794
[TBL] [Abstract][Full Text] [Related]
51. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities.
Martinelli I; Battaglioli T; Bucciarelli P; Passamonti SM; Mannucci PM
Circulation; 2004 Aug; 110(5):566-70. PubMed ID: 15262837
[TBL] [Abstract][Full Text] [Related]
52. D-Dimer Levels and Vitamin K Antagonist Therapy in Deep Vein Thrombosis of the Legs.
Park JK; Koo do H; Yoon DH; Lee JN
Ann Vasc Surg; 2016 Jul; 34():119-34. PubMed ID: 27177705
[TBL] [Abstract][Full Text] [Related]
53. What is the optimal duration of treatment for DVT? An update on evidence-based medicine of treatment for DVT.
East AT; Wakefield TW
Semin Vasc Surg; 2010 Sep; 23(3):182-91. PubMed ID: 20826296
[TBL] [Abstract][Full Text] [Related]
54. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
[TBL] [Abstract][Full Text] [Related]
55. D-dimer levels and risk of recurrent venous thromboembolism.
Eichinger S; Minar E; Bialonczyk C; Hirschl M; Quehenberger P; Schneider B; Weltermann A; Wagner O; Kyrle PA
JAMA; 2003 Aug; 290(8):1071-4. PubMed ID: 12941680
[TBL] [Abstract][Full Text] [Related]
56. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.
Prandoni P; Vedovetto V; Ciammaichella M; Bucherini E; Corradini S; Enea I; Cosmi B; Mumoli N; Visonà A; Barillari G; Bova C; Quintavalla R; Zanatta N; Pedrini S; Villalta S; Camporese G; Testa S; Parisi R; Becattini C; Cuppini S; Pengo V; Palareti G;
Thromb Res; 2017 Jun; 154():35-41. PubMed ID: 28407492
[TBL] [Abstract][Full Text] [Related]
57. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.
Eichinger S; Heinze G; Jandeck LM; Kyrle PA
Circulation; 2010 Apr; 121(14):1630-6. PubMed ID: 20351233
[TBL] [Abstract][Full Text] [Related]
58. The prediction role of D-dimer in recurrence of venous thromboembolism 1-year after anticoagulation discontinuing following idiopathic deep vein thrombosis.
Tamizifar B; Oghab P; Esfahani MA
J Res Med Sci; 2014 Jul; 19(7):586-91. PubMed ID: 25364355
[TBL] [Abstract][Full Text] [Related]
59. Residual venous obstruction in patients with a single episode of deep vein thrombosis and in patients with recurrent deep vein thrombosis.
Galli M; Ageno W; Squizzato A; Dentali F; Manfredi E; Steidl L; Venco A
Thromb Haemost; 2005 Jul; 94(1):93-5. PubMed ID: 16113790
[TBL] [Abstract][Full Text] [Related]
60. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism.
Hoke M; Kyrle PA; Minar E; Bialonzcyk C; Hirschl M; Schneider B; Kollars M; Weltermann A; Eichinger S
Thromb Haemost; 2005 Oct; 94(4):787-90. PubMed ID: 16270631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
